ACAD
38.03
-0.64
-1.66%
AEMD
0.196
-0.01
-4.6341%
APRI
1.77
-0.01
-0.56%
ARNA
4.64
-0.02
-0.43%
ATEC
1.43
+0.02
+1.42%
CNAT
6.43
-0.22
-3.31%
CRXM
0.35
+0.06
+20.69%
CYTX
1.11
-0.03
-2.63%
DXCM
67.4
-0.53
-0.78%
GNMK
10.86
-2.02
-15.68%
HALO
15.3
-0.22
-1.42%
ILMN
191.16
-1.86
-0.96%
INNV
0.15
0.00
0.00%
INO
10.04
-0.28
-2.76%
ISCO
0.057
-0.001
-0.870%
ISIS
65.33
-0.98
-1.48%
LGND
85.85
-1
-1.15%
LPTN
2.26
+0.03
+1.35%
MBVX
3.55
+0.05
+1.43%
MEIP
2.12
0.00
0.00%
MNOV
4.45
-0.51
-10.28%
MRTX
27.59
-0.21
-0.76%
MSTX
0.472
-0.009
-1.871%
NBIX
42.49
-1.12
-2.57%
NUVA
41.55
-1.18
-2.76%
ONCS
0.31
0.00
-1.59%
ONVO
4.56
-0.16
-3.39%
OREX
7.54
-0.26
-3.33%
OTIC
31.86
-0.52
-1.61%
QDEL
23.7
-0.9
-3.66%
RCPT
167.38
-0.59
-0.35%
RGLS
17.3
+0.12
+0.70%
RMD
71.88
-0.37
-0.51%
SCIE
0.025
-0.002
-7.063%
SPHS
0.81
-0.05
-5.81%
SRNE
11.31
+0.16
+1.43%
TROV
8.53
+1.43
+20.14%
VICL
0.94
-0.01
-1.05%
VOLC
17.99
0.00
0.00%
ZGNX
1.58
-0.02
-1.25%
ACAD
38.03
-0.64
-1.66%
AEMD
0.196
-0.01
-4.6341%
APRI
1.77
-0.01
-0.56%
ARNA
4.64
-0.02
-0.43%
ATEC
1.43
+0.02
+1.42%
CNAT
6.43
-0.22
-3.31%
CRXM
0.35
+0.06
+20.69%
CYTX
1.11
-0.03
-2.63%
DXCM
67.4
-0.53
-0.78%
GNMK
10.86
-2.02
-15.68%
HALO
15.3
-0.22
-1.42%
ILMN
191.16
-1.86
-0.96%
INNV
0.15
0.00
0.00%
INO
10.04
-0.28
-2.76%
ISCO
0.057
-0.001
-0.870%
ISIS
65.33
-0.98
-1.48%
LGND
85.85
-1
-1.15%
LPTN
2.26
+0.03
+1.35%
MBVX
3.55
+0.05
+1.43%
MEIP
2.12
0.00
0.00%
MNOV
4.45
-0.51
-10.28%
MRTX
27.59
-0.21
-0.76%
MSTX
0.472
-0.009
-1.871%
NBIX
42.49
-1.12
-2.57%
NUVA
41.55
-1.18
-2.76%
ONCS
0.31
0.00
-1.59%
ONVO
4.56
-0.16
-3.39%
OREX
7.54
-0.26
-3.33%
OTIC
31.86
-0.52
-1.61%
QDEL
23.7
-0.9
-3.66%
RCPT
167.38
-0.59
-0.35%
RGLS
17.3
+0.12
+0.70%
RMD
71.88
-0.37
-0.51%
SCIE
0.025
-0.002
-7.063%
SPHS
0.81
-0.05
-5.81%
SRNE
11.31
+0.16
+1.43%
TROV
8.53
+1.43
+20.14%
VICL
0.94
-0.01
-1.05%
VOLC
17.99
0.00
0.00%
ZGNX
1.58
-0.02
-1.25%
Home » Raymond Price-Bio

Raymond Price-Bio

Ray Price is Business Development Director for BioSeek, a biotech company specializing in using primary human cells to accelerate the drug discovery and development process. Ray has 12 years of experience in the pharmaceutical industry, implementing business strategies for both lead therapeutic compounds and proprietary assay systems, including the scientific due diligence as well as financial modeling of potential partnerships. He completed his executive MBA at INSEAD in Paris, France, and has work experience in Japan (Fujisawa/Astellas), the US, and France. He has a Ph.D. in Pharmacology from Vanderbilt University and extensive R&D and drug development experience, including being lead investigator on two SBIR (small business) grants from the NIH. He was principal consultant in his own company doing business development and medical writing for industry and academic investigators, where he wrote or edited over 2000 scientific, regulatory, and business documents in a wide variety of therapeutic areas. He is a native English speaker, has functional Japanese fluency, and beginning French ability.